To carry out their activities, Research Teams of the Frédéric Joliot Institute for Life Sciences have developed high-profile technological platforms in many areas : biomedical imaging, structural biology, metabolomics, High-Throughput screening, level 3 microbiological safety laboratory...
Within the Institute, the "Funding Research and Technology Transfer" team is at your disposal to identify the scientists and the skills you need to set up a joint project, to define the terms of a collaboration contract or study.
Whether you are an academic, a SME or an industrialist, our team informs and advices you about the possibilities of consortium assembly, technology transfer, patent licensing or use of our platforms.
The team is also at the disposal of the researchers of the institute to accompany them in achieving their valorization objectives.
All the news of the Institute of life sciences Frédéric Joliot
A NeuroSpin team, in collaboration with researchers from SHFJ and MIRCen (CEA-Jacob), is identifying a predictive indicator of the potentially deleterious effect of devices using ultrasound to deliver drugs to the brain.
Researchers at the Institut de Recherche Saint Louis and I2BC identify a protein motif responsible for the specificity of insertion of retrotransposon Ty1 in the yeast genome. This motif could be used to adapt gene therapy vectors and limit their mutagenic potential.
The international OpenGATE collaboration, involving the BioMaps laboratory(SHFJ), has demonstrated the value of the GATE numerical simulation platform in clinical use for cancer treatment planning using hadrontherapy.
In an article published in the Journal of Medicinal Chemistry, the Venomics consortium led by a SIMoS team shows the interest of creating toxin banks to identify molecules regulating therapeutic targets.
The discovery of myriads of new species of bacteria and archaea, linked to the explosion of metagenomics, is leading microbiologists to consider rethinking how to map certain branches of life. Tools, such as the phylopeptidomics developed at Li2D, could help them do so.
Researchers from the I2BC (SB2SM), in collaboration with CNRS (LCP, ICMMO) have designed an original artificial photosynthesis approach, based on the use of semiconductor nanopolymers composed of PolyDiPhenylButadiyne, capable of reproducing the full photo-redox reaction of plant Photosystem II, that is the production of O2 by photo-oxidation of water and the reduction of a quinone.
In order to optimize the amplification of quality inactivated virus, for the manufacture of a vaccine, a team from SPI (CEA Marcoule) used mass spectrometry to analyze the dynamics of the proteome of SARS-CoV-2 infected cells, at two multiplicities of infection. With more than 3,220 identified host proteins, researchers are also starting to decipher the processes and cellular networks impacted by this virus.
Researchers from the BioMaps unit based at the SHFJ have developed an imaging protocol to study in vivo the hepatobiliary transport capacity responsible for the elimination of many drugs and to better understand the hepatotoxicity of certain drugs.
Researchers from the LMC have developed a new series of iminosydnones that can split in two and release two fluorophores. They are providing a proof of concept that this "click and release" reaction can be triggered in living cells.
SIMoS researchers, in collaboration with Genopole, Excellgene, Vaxeal holding SA (Switzerland), used a large-scale approach to map and characterize the response of CD4 T-cells from healthy donors, against two proteins from the Ebola-Zaire virus. They observed a strong response to the viral nucleoprotein (NP) and suggest that components of NP may be included in the design of new Ebola vaccines.
CEA is a French government-funded technological research organisation in four main areas: low-carbon energies, defense and security, information technologies and health technologies. A prominent player in the European Research Area, it is involved in setting up collaborative projects with many partners around the world.